Estonian healthtech company LSMedical is developing a nanoparticle-based contrast agent designed to work across both CT and MRI imaging in a single injection, aiming to extend safe diagnostics to patients for whom current agents are unsuitable.
LSMedical, a member of Tehnopol’s HealthTech community in Estonia, is working on a next-generation contrast agent intended to replace the separate iodine-based and gadolinium-based compounds currently used in computed tomography and magnetic resonance imaging respectively. The company says its single nanoparticle-based agent can serve both imaging modalities and is designed to clear from the body rapidly, reducing the risk of accumulation. The solution is also built to be compatible with existing medical equipment and imaging protocols, removing the need for infrastructure changes at healthcare facilities.
The target patient groups include people with multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, stroke and cancer who require repeated examinations, as well as pregnant women, children and patients with kidney disease, all of whom face limitations with agents currently on the market. LSMedical holds protected intellectual property covering the agent’s composition, synthesis, dual-modality use, elimination and manufacturing, and says its formulation does not rely on rare-earth element supply chains.
The company is conducting in vivo and toxicological studies with international partners, including King’s College London and the Karolinska Institute in Sweden, and is working with clinics in the United States to design future clinical trials and prepare for Phase I human studies. LSMedical was founded by materials scientist Liis Seinberg, who has more than 20 years of experience in contrast agent synthesis and previously founded medical device manufacturer Nordic Esthetic Group. CFO Gert Seinberg brings 15 years of startup financial management experience, including roles at Starship Technologies and Snyk.
In 2026, LSMedical was selected for the NATO DIANA Innovation Accelerator, a programme supporting dual-use and defence technologies, chosen from 3,680 applicants for a cohort of 150 companies across the Alliance. The company identifies securing long-term investors in Estonia and limited public investment support for the medical sector as its main near-term challenges.
LSMedical’s stated priorities over the coming years are completing preclinical safety studies, bringing manufacturing to Good Manufacturing Practice standards and initiating its first clinical trials in humans. Within five years, the company aims to be in late-stage clinical trials and advancing toward market authorisation in both Europe and the United States.
Source: tehnopol.ee





